Show simple item record

dc.contributor.authorSalem, Anwar
dc.contributor.authorAlotaibi, Mashael
dc.contributor.authorMroueh, Rima
dc.contributor.authorBasheer, H.A.
dc.contributor.authorAfarinkia, Kamyar
dc.date.accessioned2021-01-18T14:27:51Z
dc.date.accessioned2021-01-20T11:54:14Z
dc.date.available2021-01-18T14:27:51Z
dc.date.available2021-01-20T11:54:14Z
dc.date.issued2021-01
dc.identifier.citationSalem A, Alotaibi M, Mroueh R et al (2021) CCR7 as a therapeutic target in Cancer. Biochimica et Biophysica Acta - Reviews on Cancer. 1875(1): 188499.en_US
dc.identifier.urihttp://hdl.handle.net/10454/18319
dc.descriptionYesen_US
dc.description.abstractThe CCR7 chemokine axis is comprised of chemokine ligand 21 (CCL21) and chemokine ligand 19 (CCL19) acting on chemokine receptor 7 (CCR7). This axis plays two important but apparently opposing roles in cancer. On the one hand, this axis is significantly engaged in the trafficking of a number of effecter cells involved in mounting an immune response to a growing tumour. This suggests therapeutic strategies which involve potentiation of this axis can be used to combat the spread of cancer. On the other hand, the CCR7 axis plays a significant role in controlling the migration of tumour cells towards the lymphatic system and metastasis and can thus contribute to the expansion of cancer. This implies that therapeutic strategies which involve decreasing signaling through the CCR7 axis would have a beneficial effect in preventing dissemination of cancer. This dichotomy has partly been the reason why this axis has not yet been exploited, as other chemokine axes have, as a therapeutic target in cancer. Recent report of a crystal structure for CCR7 provides opportunities to exploit this axis in developing new cancer therapies. However, it remains unclear which of these two strategies, potentiation or antagonism of the CCR7 axis, is more appropriate for cancer therapy. This review brings together the evidence supporting both roles of the CCR7 axis in cancer and examines the future potential of each of the two different therapeutic approaches involving the CCR7 axis in cancer.en_US
dc.language.isoenen_US
dc.relation.isreferencedbyhttps://doi.org/10.1016/j.bbcan.2020.188499en_US
dc.rights© 2021 Elsevier. Reproduced in accordance with the publisher's self-archiving policy. This manuscript version is made available under the CC-BY-NC-ND 4.0 license (https://creativecommons.org/licenses/by-nc-nd/4.0/)en_US
dc.subjectChemokineen_US
dc.subjectCCR7en_US
dc.subjectCCL19en_US
dc.subjectCCL21en_US
dc.subjectCanceren_US
dc.subjectMetastasisen_US
dc.subjectImmunotherapyen_US
dc.subjectTherapyen_US
dc.titleCCR7 as a therapeutic target in Canceren_US
dc.status.refereedYesen_US
dc.date.Accepted2020-12-24
dc.date.application2020-12-29
dc.typeArticleen_US
dc.date.EndofEmbargo2021-12-30
dc.type.versionAccepted manuscripten_US
dc.description.publicnotesThe full-text of this article will be released for public view at the end of the publisher embargo on 30 Dec 2021.en_US
dc.date.updated2021-01-18T14:28:06Z
refterms.dateFOA2021-01-20T12:48:13Z
dc.openaccess.statusGreenen_US


Item file(s)

Thumbnail
Name:
salem_et_al_2021.pdf
Embargo:
2021-12-30
Size:
1.737Mb
Format:
PDF
Description:
Main article
Thumbnail
Name:
1-s2.0-S0304419X20302183-main.pdf
Size:
1.739Mb
Format:
PDF
Description:
Keep suppressed - has watermark ...

This item appears in the following Collection(s)

Show simple item record